Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28526559 | 0.80 | ABCB1 (0.40) | ABCB1RIPK1GPR119NR1H2NR1H3 | |
| SCHEMBL20835514 | 0.80 | ABCB1 (0.40) | ABCB1RIPK1GPR119NR1H2NR1H3 | |
| SCHEMBL20835838 | 0.80 | ABCB1 (0.45) | ABCB1RIPK1GPR119NR1H2NR1H3 | |
| SCHEMBL28285321 | 0.79 | GPR119 (0.43) | ABCB1RIPK1GPR119NR1H2NR1H3 | |
| SCHEMBL5152764 | 0.79 | GPR119 (0.44) | ABCB1RIPK1GPR119NR1H2NR1H3 | |
| SCHEMBL16004572 | 0.78 | RORC (0.44) | ABCB1RIPK1GPR119NR1H2NR1H3 | |
| SCHEMBL28518960 | 0.75 | RIPK1 (0.40) | ABCB1RIPK1GPR119NR1H2NR1H3 | |
| SCHEMBL28523788 | 0.74 | ABCB1 (0.46) | ABCB1RIPK1GPR119NR1H2NR1H3 | |
| SCHEMBL1104528 | 0.72 | YAP1 (0.48) | — | |
| SCHEMBL29388249 | 0.70 | GPR119 (0.38) | ABCB1GPR119RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| CN-109476639-B | Pyrrolidine derivatives | 橘生药品工业股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | ABCB1 1573/4885RIPK1 1917/4885GPR119 164/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | ABCB1 1573/4885RIPK1 1917/4885GPR119 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.